**Business Performance:** MedPlus reported robust financial results for the quarter and half-year.

Q2FY26 revenue reached ₹1,679.3 Cr (+6.5% YoY, +8.9% QoQ), with H1FY26 revenue at ₹3,222 Cr (+5.1% YoY). Gross Margin stood at 26.1%. Operating EBITDA for Q2FY26 grew 20% YoY to ₹88.7 Cr, while H1FY26 Operating EBITDA surged 37.6% YoY to ₹161.5 Cr.

PAT for Q2FY26 jumped 43.4% YoY to ₹55.5 Cr, and H1FY26 PAT rose 84.5% YoY to ₹97.9 Cr.

Older stores (12+ months) demonstrated 2.2% revenue growth and an 11.8% EBITDA margin. **Growth Drivers or Strategy:** The company is focused on cluster-based expansion for deeper market penetration and leveraging its omni-channel platform for broader reach, retention, and <2-hour deliveries.

Expanding its private label portfolio (1,450+ SKUs) is crucial for higher margins and increased customer wallet share. **Recent Developments:** MedPlus added a net of 117 stores in Q2FY26, expanding its network to 4,930 stores across 750+ cities.

Q2FY26 operating cash flow was ₹126.1 Cr, with ₹608.5 Cr in closing cash. **Key Financial Metrics:** Q2FY26 highlights include 6.5% YoY revenue growth, 20% YoY Operating EBITDA increase, and 43.4% YoY PAT surge. **Management Commentary / Outlook:** MedPlus remains "Poised for Growth," emphasizing continuous store expansion, profitable omni-channel services, and a growing private label offering.